A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non–Small Cell Lung Cancer: JCOG2510 (PRIME-CRT)
Clinical Lung Cancer · 2026-11 · 27 (9) · 39-43
DOI: 10.1016/j.cllc.2026.09.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Lung Cancer, 2026-11. Verfasst von Kota Kawabata und 17 weiteren Autor:innen. Beteiligte Einrichtung: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Induction Chemotherapy. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center.
Abstract (Originalsprache)
BACKGROUND: Definitive concurrent chemoradiotherapy (cCRT) followed by durvalumab consolidation is the current standard of care for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). However, survival outcomes in this setting remain unsatisfactory. Although the PACIFIC trial improved outcomes, further intensification of systemic therapy may be required to improve long-term survival. Preclinical and perioperative clinical evidence suggests that introducing immunotherapy in the presence of an intact primary tumor may enhance antitumor immune responses. Recently, early-phase studies have reported the feasibility and potential efficacy of induction chemo-immunotherapy followed by cCRT; however, its clinical benefit has not been confirmed in a phase III trial. PATIENTS AND METHODS: This multicenter, randomized, phase III trial is designed to determine whether the addition of induction chemo-immunotherapy to the current standard strategy of cCRT followed by durvalumab consolidation improves survival outcomes in patients with unresectable LA-NSCLC. Previously untreated patients with unresectable LA-NSCLC without activating EGFR mutations are randomized 1:1 to receive either cCRT followed by durvalumab consolidation or induction chemo-immunotherapy followed by cCRT and durvalumab consolidation. Randomization is adjusted for age, clinical stage, programmed death-ligand 1 expression, and institution. The primary endpoints are progression-free and overall survival. Secondary endpoints include objective response rate, proportion of patients proceeding to cCRT after induction therapy, and adverse events. A total of 212 patients will be enrolled from 60 institutions over 5 years. CONCLUSION: The results of this trial should clarify whether the addition of induction chemo-immunotherapy can enhance curative potential and lead to improved overall survival in patients with unresectable LA-NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
- Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan. Electronic address: masuda_ken@med.kurume-u.ac.jp.
- Department of Respiratory Medicine, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
- Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University School of Medical Sciences, Aichi, Japan.
Förderung
- National Cancer Center
Zitieren
APA
Kawabata, K., Masuda, K., Miura, K., Saida, Y., Ko, R., Akamatsu, H., Horinouchi, H., Chiba, T., Okuma, K., Harada, H., Shiraishi, Y., Goto, Y., Nomura, S., Mitome, N., Fukuda, H., Okamoto, I., Kenmotsu, H., & Lung Cancer Study Group of the Japan Clinical Oncology Group (2026). A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non–Small Cell Lung Cancer: JCOG2510 (PRIME-CRT). Clinical Lung Cancer, 27(9), 39-43. https://doi.org/10.1016/j.cllc.2026.09.007
Vancouver
Kawabata K, Masuda K, Miura K, Saida Y, Ko R, Akamatsu H, et al. A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non–Small Cell Lung Cancer: JCOG2510 (PRIME-CRT). Clinical Lung Cancer. 2026;27(9):39-43. doi:10.1016/j.cllc.2026.09.007
BibTeX
@article{Kawabata2026,
author = {Kawabata, Kota and Masuda, Ken and Miura, Keita and Saida, Yu and Ko, Ryo and Akamatsu, Hiroaki and Horinouchi, Hidehito and Chiba, Takahito and Okuma, Kae and Harada, Hideyuki and Shiraishi, Yoshimasa and Goto, Yasushi and Nomura, Shogo and Mitome, Noriko and Fukuda, Haruhiko and Okamoto, Isamu and Kenmotsu, Hirotsugu and Lung Cancer Study Group of the Japan Clinical Oncology Group, Lung Cancer Study Group of the Japan Clinical Oncology Group},
title = {A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non–Small Cell Lung Cancer: JCOG2510 (PRIME-CRT)},
journal = {Clinical Lung Cancer},
year = {2026},
volume = {27},
number = {9},
pages = {39--43},
doi = {10.1016/j.cllc.2026.09.007}
}
EUVIMED